Video-based research in pediatric urology visits revealed high participant interest, with over 70% consent rate, highlighting the importance of communication studies. Current interpretation ...

Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential ...

Optilume DCB combines mechanical dilation with paclitaxel coating for effective urethral patency maintenance in recurrent anterior urethral strictures. ROBUST III trial shows significant improvements ...

A 400 mg BID dose of oral testosterone undecanoate significantly increases serum testosterone levels and improves symptoms in hypogonadal men. The study observed decreased sex hormone binding globulin ...

The TRAVERSE trial is the largest randomized placebo-controlled study on testosterone therapy, impacting clinical perspectives on its risks and benefits. The study alleviates concerns about ...

IPP from Boston Scientific and Coloplast significantly increased penile length and width post-surgery compared to preoperative measurements. The study involved 151 patients, with a mean age of 64.4 ...

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS. In this interview, ...

The "drain and retain" technique is safe for IPP revision surgeries without infection, avoiding morbidity from reservoir removal. Study across seven US centers showed similar infection rates for ...

MED3000 gel is FDA-cleared for over-the-counter use and improves erectile dysfunction outcomes for men and partners. A 12-week study across multiple countries showed significant improvements in SEP ...

PSMA-PET imaging enables molecular-level detection of prostate cancer cells, often before CT or MRI abnormalities are visible. Sensitivity of PSMA-PET/CT in recurrent prostate cancer can reach 97% ...

Five-fraction SBRT showed noninferiority to conventional radiotherapy in localized prostate cancer, with 95.8% of patients free from failure at five years. SBRT offers a shorter treatment duration, ...

The NRG-GU011 trial evaluates relugolix plus SBRT versus SBRT alone in men with PSA recurrence and PSMA-PET-detected metastases. The study addresses whether targeted radiation can delay hormone ...